PharmTech Drug Digest 11.20
News|Articles|September 9, 2013

Mylan Completes Expansion of Vermont Transdermal Patch Facility

Mylan completes expansion of its transdermal patch facility in Vermont.

Mylan has completed an 85,000 ft2, three-story expansion project at its transdermal patch facility in St. Albans, Vermont. The facility, operated by Mylan Technologies Inc. (MTI), is a subsidiary of Mylan that focuses on transdermal drug delivery. Mylan's investment includes expanded R&D capabilities and additional manufacturing and laboratory space. In addition, Mylan is in the process of adding more than 160 new positions to its St. Albans-based workforce.

The 14-month expansion project has increased MTI's total operating space to more than 391,000 ft2.

Source: Mylan


Related to this article

white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Green Chemistry Supply and Demand in Sustainable Pharma
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.